The results of a 59-patient trial of psilocybin versus escitalopram (a common SSRI) for depression published this week, attracting a great deal of attention. Commentary on this paper constitutes the bulk of this week’s bulletin, which we’re dubbing a Special Edition for that purpose. A long-awaited study that pitted psilocybin against the SSRI escitalopram (brand names include Cipralex, Lexapro)…
